Collateral damage of using colistin in hospitalized patients on emergence of colistin-resistant Escherichia coli and Klebsiella pneumoniae colonization and infection

Antimicrobial Resistance and Infection Control
W WangchindaVisanu Thamlikitkul

Abstract

Colistin has been used for therapy of carbapenem-resistant Gram-negative infections in Thailand, especially carbapenem-resistant A. baumannii and P. aeruginosa, for more than 10 years. However, the prevalence of colistin-resistant A. baumannii or P. aeruginosa is still less than 5%. Colistin-resistant Enterobacteriaceae has been increasingly reported globally over the past few years and the use of colistin in food animals might be associated with an emergence of colistin resistance in Enterobacteriaceae. This study aimed to determine the effect of colistin exposure in hospitalized patients who received colistin on development of colistin-resistant (CoR) Escherichia coli (EC) or Klebsiella pneumoniae (KP) colonization and infection. A prospective observational study was performed in adult hospitalized patients at Siriraj Hospital who received colistin for treatment of infections during December 2016 and November 2017. The surveillance culture samples were collected from the stool and the site of infection of each patient who received colistin at the study enrollment, days 3 and 7 after the study enrollment, and once a week thereafter for determination of CoR EC and CoR KP. CoR EC and CoR KP were also tested for a presence of mcr...Continue Reading

References

Sep 1, 1986·Antimicrobial Agents and Chemotherapy·J R WingardR Saral
Jul 1, 1985·The Journal of Infectious Diseases·C H Tancrède, A O Andremont
Feb 20, 2007·The Journal of Antimicrobial Chemotherapy·Anastasia AntoniadouHelen Giamarellou
Sep 24, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·F KontopidouH Giamarellou
Oct 4, 2012·Expert Review of Anti-infective Therapy·Silpak BiswasJean-Marc Rolain
May 1, 2013·Antimicrobial Agents and Chemotherapy·Teysir HalabyChristina M J E Vandenbroucke-Grauls
Dec 17, 2014·Frontiers in Microbiology·Abiola O OlaitanJean-Marc Rolain
Jan 30, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zubair A QureshiYohei Doi
Jun 1, 2015·Journal of Infection and Chemotherapy : Official Journal of the Japan Society of Chemotherapy·Juthamas InchaiChaicharn Pothirat
Jun 13, 2015·Yonsei Medical Journal·Yoonjung KimKyungwon Lee
Aug 19, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·D R GiacobbeM Tumbarello
Dec 30, 2015·International Journal of Antimicrobial Agents·Abiola Olumuyiwa OlaitanSerge Morand
Mar 5, 2016·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Patrice NordmannLaurent Poirel
Jul 16, 2016·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Basil Britto XavierSurbhi Malhotra-Kumar
Aug 12, 2017·Euro Surveillance : Bulletin Européen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin·Alessandra CarattoliChiara Francesca Magistrali
Aug 26, 2017·Journal of Global Antimicrobial Resistance·Emese JuhászKatalin Kristóf
Mar 23, 2018·Nature Communications·Ruobing WangFrancois Balloux
Jun 24, 2018·Journal of Global Antimicrobial Resistance·Warawan EiamphungpornVisanu Thamlikitkul

❮ Previous
Next ❯

Citations

Apr 5, 2019·PloS One·Jocelin Merida-VieyraAlejandra Aquino-Andrade
May 2, 2020·Antibiotics·Paul S Hoffman
Oct 9, 2019·International Journal of Environmental Research and Public Health·Visanu ThamlikitkulWilai Chiemchaisri
Nov 24, 2019·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Yaakov DicksteinUNKNOWN AIDA Study Group
Apr 30, 2021·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Majid Taati MoghadamShahla Shahbazi

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

SPSS Statistics

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.